相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
50.0%
招募中
1
50.0%
暂无批准数据
- Leerink Partners analyst David Risinger raises Tectonic Therapeutic's price target to $118, citing TX45's potential as a best-in-class treatment for PH-HFpEF. - TX45, a long-acting relaxin therapeutic, targets both PH-HFpEF and PH-HFrEF patient populations, addressing significant unmet medical needs in pulmonary hypertension treatment. - Phase 1b trial results for TX45 are expected in Q1 2025, with the company's strategic expansion into PH-HFrEF patients showing strong enrollment and physician interest.
- Tectonic Therapeutic's TX45 demonstrated significant improvements in left ventricular function and pulmonary hemodynamics in patients with PH-HFpEF. - The Phase 1b trial showed a 17.9% reduction in pulmonary capillary wedge pressure (PCWP) in the overall study population. - In a subpopulation with more severe disease (CpcPH), TX45 achieved a greater than 30% reduction in pulmonary vascular resistance (PVR). - TX45 was well-tolerated, with no serious adverse events reported, supporting its continued development in the Phase 2 APEX trial.
- Tectonic Therapeutic reported positive topline data from its Phase Ia trial of TX45 for Group 2 pulmonary hypertension with preserved ejection fraction (PH-HFpEF). - The trial demonstrated that TX45 was safe and well-tolerated in healthy subjects, with minimal adverse events and no immune-mediated clearance observed. - A strong pharmacokinetic/pharmacodynamic (PK/PD) relationship was established, enabling the selection of appropriate doses for the upcoming Phase II trial. - The Phase II trial, named APEX, has commenced subject screening and will evaluate the effect of TX45 on PH-HFpEF patients with topline results expected in 2026.
